Table 2.

Safety Data

Event	Recipients (n=30)
Serious Adverse Events*
Total Events	32
Patients with SAE (n,%)	23 (67%)
Treatment-related SAEs (n)	1
AEs requiring treatment discontinuation	0
Patients with episode of acute rejection requiring treatment* (n,%)
Lung	3 (23%)
Kidney	0
Heart	4 (67%)
Kidney-Pancreas	0
Episodes of acute rejection requiring treatment* (n)
Lung	3
Kidney	0
Heart	7
Kidney-Pancreas	0
Laboratory Adverse Event (n,%)
ALT Elevation*
Grade 1	9 (30%)
Grade 2	2 (7%)
Grade 3	4 (13%)
Grade 4	1 (3%)
Bilirubin Elevation
Grade 1	1 (3%)
Grade 2	6 (20%)
Grade 3	1 (3%)
Grade 4	2 (7%)
Creatine Kinase Elevation*
Grade 1	2 (7%)
Grade 2	14 (47%)
Grade 3	1 (3%)
Grade 4	0

^*see supplementary appendix for details of SAEs, rejection episodes, ALT and CK elevations